1 insider bought €4,089 of shares over the last 90 days, the latest by 윤종필, filed 02 Oct 2026.
Who traded when
BuySaleSince the insiders bought
- -6.7%Entry ₩3,895 · Close 30 Oct 2026 ₩3,635
- -2.8%Entry ₩3,740 · Close 30 Oct 2026 ₩3,635
- -2.8%Entry ₩3,740 · Close 30 Oct 2026 ₩3,635
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 1,000 sharesShareKRXDART:20261002000549Canonical exit: 31 Dec 2026 (T+90)
- 700 sharesShareKRXDART:20260825000152Canonical exit: 23 Nov 2026 (T+90)
- 1,600 sharesShareKRXDART:20260716000404Canonical exit: 14 Oct 2026 (T+90)
- 234,271 sharesShareKRXDART:20260612000563Canonical exit: 10 Sept 2026 (T+90)
- 700 sharesShareKRXDART:20260612000576Canonical exit: 10 Sept 2026 (T+90)
- 499,227 sharesKRXDART:20260612000634Canonical exit: 10 Sept 2026 (T+90)
- 300 shares@ ₩3,910.000.0010% mcap39.4% of flowShareKRXDART:20260604000004Canonical exit: 31 Aug 2026 (T+90)
- 5,744 sharesShareKRXDART:20260522000226Canonical exit: 20 Aug 2026 (T+90)
- 400 shares@ ₩4,460.000.0015% mcap60.6% of flowShareKRXDART:20260427000604Canonical exit: 2 Jul 2026 (T+90)
- 400 shares@ ₩4,460.000.0015% mcap12.1% of flowShareKRXDART:20260423000137Canonical exit: 2 Jul 2026 (T+90)
- 2,793 shares@ ₩4,587.37630.011% mcap87.9% of flowShareKRXDART:20260423000434Canonical exit: 2 Jun 2026 (T+90)
- ●Executives0DART
- ●Executives0DART
- 1,300 sharesShareKRXDART:20260203000396Canonical exit: 4 May 2026 (T+90)
- 1,300 sharesShareKRXDART:20260203000384Canonical exit: 4 May 2026 (T+90)
- 2,000 sharesShareKRXDART:20260203000376Canonical exit: 4 May 2026 (T+90)
- 3,501 sharesShareKRXDART:20260122000278Canonical exit: 22 Apr 2026 (T+90)
- 21,860 sharesShareKRXDART:20260116000211Canonical exit: 16 Apr 2026 (T+90)
- 298,627 sharesKRXDART:20250709000133Canonical exit: 28 Aug 2025 (T+90)
- 16,906 sharesShareKRXDART:20250708000235Canonical exit: 6 Oct 2025 (T+90)
- 11,099 sharesShareKRXDART:20241216000218Canonical exit: 16 Mar 2025 (T+90)
- 11,198 sharesShareKRXDART:20241126000328Canonical exit: 24 Feb 2025 (T+90)
- ShareKRXDART:20240911000268Canonical exit: 5 Dec 2024 (T+90)
- ShareKRXDART:20240903000056Canonical exit: 26 Nov 2024 (T+90)
- ShareKRXDART:20240628000335Canonical exit: 25 Sept 2024 (T+90)
25 of 41 declarations
About Meta Biomed Co., Ltd.
Sixteen of the 41 filings at 메타바이오메드 (Meta Biomed Co., Ltd.) carry the signature of 오지수, filed as 사장, and every one is a purchase. 윤종필 (상무이사) adds 7, also purchases, and 한국증권금융 (대량보유자) 7, including 6 purchases. The record thus holds 32 purchases against a single sale, or 97% purchases among open-market trades.
Only four purchases carry an amount, EUR 10,140 in all: EUR 7,431 for 오지수 on March 4, 2026, then EUR 1,022 each for 윤종필 and 오지수 on April 3, 2026. From February 3 to March 4, 2026, 4 filers bought.
Read moreShow less
The year 2026 supplied 18 filings, against 8 in 2024, 6 in 2023, 5 in 2022 and 2 in both 2021 and 2025. That is also the total for the last twelve months, 16 of them purchases. Filings are published with a marked lag, a median of 21 days across 12 measured. The company, South Korean and active in health care, is valued at KRW 99.7 billion. Eleven purchases have a 90-day result: a median of 3.1%, 55% positive, a measure of the past and not a forecast.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
